GenMark Diagnostics to Present at Canaccord Genuity 32nd Annual Growth Conference
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc., (NASDAQ:GNMK) a leading provider of
automated, multiplex molecular diagnostic testing systems, will present
at the Canaccord Genuity 32nd Annual Growth Conference to be held at the
InterContinental Boston hotel in Boston, Massachusetts today.
Hany Massarany, President and Chief Executive Officer will present at
1:30 p.m. Eastern time (10:30 a.m. Pacific time) with a question and
answer session scheduled immediately following the presentation. During
the presentation, the company will discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously disclosed.
A live webcast and audio archive of the presentation will be available
A replay of the webcast will be available on the company's website for
About GenMark Diagnostics, Inc.
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. Utilizing
GenMark's proprietary eSensor® detection technology, GenMark's eSensor®
XT-8 system is designed to support a broad range of molecular diagnostic
tests with a compact, easy-to-use workstation and self-contained,
disposable test cartridges. GenMark currently markets three tests that
are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Warfarin
Sensitivity Test, and Thrombophilia Risk Test. A number of other tests,
including HCV Genotyping, 2C19 and KRAS, are in development. For more
information, visit www.genmarkdx.com.
Safe Harbor Statement
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements, including, but not
limited to, those regarding our growth strategy, are all subject to
risks and uncertainties that could cause our actual results and
financial position to differ materially. Some of these risks and
uncertainties include, but are not limited to, risks related to our
history of operating losses, the need for further financing and our
ability to access the necessary additional capital for our business,
inherent risk and uncertainty in the protection of intellectual property
rights, and regulatory uncertainties regarding approval or clearance for
our products, as well as other risks and uncertainties described under
the "Risk Factors" in our public filings with the Securities and
Exchange Commission. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances
after the date they are made.
GenMark Diagnostics, Inc.
Source: GenMark Diagnostics, Inc.
News Provided by Acquire Media
Close window | Back to top